0A4C Stock Overview
A clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Altimmune, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.03 |
| 52 Week High | US$14.82 |
| 52 Week Low | US$2.12 |
| Beta | 0.097 |
| 11 Month Change | -2.25% |
| 3 Month Change | -23.96% |
| 1 Year Change | 103.65% |
| 33 Year Change | -22.24% |
| 5 Year Change | n/a |
| Change since IPO | -47.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A4C | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -6.2% | -3.1% | -1.4% |
| 1Y | 103.6% | -25.7% | 6.3% |
Return vs Industry: 0A4C exceeded the UK Biotechs industry which returned -25.7% over the past year.
Return vs Market: 0A4C exceeded the UK Market which returned 6.3% over the past year.
Price Volatility
| 0A4C volatility | |
|---|---|
| 0A4C Average Weekly Movement | 12.3% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 11.0% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0A4C's share price has been volatile over the past 3 months.
Volatility Over Time: 0A4C's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 59 | Vipin Garg | altimmune.com |
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.
Altimmune, Inc. Fundamentals Summary
| 0A4C fundamental statistics | |
|---|---|
| Market cap | US$510.50m |
| Earnings (TTM) | -US$92.77m |
| Revenue (TTM) | US$410.00k |
1,245x
P/S Ratio-5.5x
P/E RatioIs 0A4C overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A4C income statement (TTM) | |
|---|---|
| Revenue | US$410.00k |
| Cost of Revenue | US$70.04m |
| Gross Profit | -US$69.63m |
| Other Expenses | US$23.14m |
| Earnings | -US$92.77m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.31 |
| Gross Margin | -16,982.20% |
| Net Profit Margin | -22,626.10% |
| Debt/Equity Ratio | 0% |
How did 0A4C perform over the long term?
See historical performance and comparison